Eventide Asset Management LLC Acquires New Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Eventide Asset Management LLC acquired a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 786,990 shares of the company’s stock, valued at approximately $15,150,000. Eventide Asset Management LLC owned approximately 0.92% of Syndax Pharmaceuticals as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Syndax Pharmaceuticals during the second quarter valued at about $27,000. Values First Advisors Inc. bought a new stake in shares of Syndax Pharmaceuticals during the third quarter valued at about $30,000. nVerses Capital LLC bought a new stake in shares of Syndax Pharmaceuticals during the second quarter valued at about $33,000. Quantbot Technologies LP bought a new stake in shares of Syndax Pharmaceuticals during the third quarter valued at about $49,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after purchasing an additional 541 shares in the last quarter.

Syndax Pharmaceuticals Stock Performance

NASDAQ SNDX opened at $16.51 on Friday. The stock’s 50-day moving average price is $18.47 and its two-hundred day moving average price is $19.84. Syndax Pharmaceuticals, Inc. has a 1 year low of $15.00 and a 1 year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.16 million. During the same period last year, the firm earned ($0.73) EPS. As a group, equities analysts expect that Syndax Pharmaceuticals, Inc. will post -2.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on SNDX shares. JPMorgan Chase & Co. lifted their price objective on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday, November 21st. Stifel Nicolaus boosted their price target on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. The Goldman Sachs Group boosted their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Citigroup boosted their price target on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, November 19th. Finally, Barclays boosted their price target on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, August 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.64.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).